Gunnar Fantoft, a 72-year-old entrepreneur from Aalborg, Denmark, emphasizes the critical role of early detection in fighting prostate cancer. He is married, has three children, and is a proud grandfather to five grandchildren. Gunnar founded his company, GF Inveco, in 1987 and continues to serve as its CEO today. Throughout his life, sports have been a vital aspect of his daily routine, and he still actively plays golf, tennis, and soccer.

Despite having no symptoms, Gunnar was advised by his doctor and friends to undergo a prostate-specific antigen (PSA) test. The PSA test is crucial for the early detection of prostate cancer, as it measures the concentration of PSA in the blood. Elevated levels can indicate the presence of prostate cancer.

In 2021, the PSA test revealed a very high value, prompting a PET-CT scan that confirmed his diagnosis of prostate cancer. He successfully underwent treatment with theranostics. During his treatment, Gunnar was classified as a super responder to this therapy, experiencing no side effects.